Rubicon Genomics is a biotechnology startup founded in 2000 by Dr. John Langmore and Dr. Vladimir Makarov of the University of Michigan. Now a part of Takara Bio USA, Inc., Rubicon Genomics is focused on translating laboratory knowledge of human genetics into practical medical applications.
The company's innovative technologies and strategic partnerships have positioned Rubicon as an industry leader in pre-analytical sample processing and amplification. Its core competencies in enzymology, nucleic acid chemistry, and manufacturing have been instrumental in driving innovation and building intellectual property.
With $2.00M in the last Venture Round investment received on 15 July 2015 from BroadOak Capital Partners and RCT, Rubicon Genomics is strengthening its position in the market. The company's products break the sample barriers for customers, enabling the use of less sample from diverse sources while ensuring ease of use, robustness, and speed to results.
Based in the United States, Rubicon Genomics continues to expand its product pipeline through partnerships with the academic community and customers, offering research-use products available for direct purchase from Takara Bio, distributors, or OEM partners.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $2.00M | 2 |
|
15 Jul 2015 |
| Series B | $3.50M | 3 |
|
01 Oct 2002 |
No recent news or press coverage available for Rubicon Genomics.
We care about your data, and we'd love to use cookies make your experience better.
